Printer Friendly

ALLERGAN SKIN CARE DIVISION WILL REPORT TO HAUGEN; W. RICHARD ULMER TO LEAVE ALLERGAN

 ALLERGAN SKIN CARE DIVISION WILL REPORT TO HAUGEN;
 W. RICHARD ULMER TO LEAVE ALLERGAN
 IRVINE, Calif., July 15 /PRNewswire/ -- Allergan, Inc. (NYSE: AGN) has announced that W. Richard Ulmer, corporate vice president and president of Allergan Herbert, will leave the company effective July 31. Allergan Herbert is the skin care division of Allergan, Inc. The division will now report to Chief Operating Officer Richard M. Haugen. Haugen currently has worldwide responsibility for Allergan's eye care operations.
 "Rich Ulmer has been with us for 25 years, and his contributions are too numerous to count," said President and Chief Executive Officer William C. Shepherd. "He was instrumental in the reorganization we implemented last year, and he has played a major role in many of our most important initiatives over the years. We will miss his counsel and advice."
 Allergan has been realigning all of its operation activities under Haugen, who was named COO last April. "All of our eye care operations report to Rick Haugen, and the time was right to complete the realignment by having our skin care operations under the same leadership as part of our ongoing efforts to streamline the business to improve operating efficiencies," Shepherd said.
 Allergan began its realignment program in 1990 when it implemented a new organizational structure. This new organization has streamlined the operations to reduce Selling, General and Administrative expenses in order to increase the investment in Research and Development. These efforts also included the sale last year of Humphrey Instruments and the announcement this year of a definitive agreement to sell Allergan's contact lens business in North and South America.
 "Our efforts have been aimed at pursuing those areas that provide us the greatest opportunity for growth and at reallocating our resources into technologies that will result in new products to benefit people worldwide," said Haugen.
 Allergan will continue to strengthen its leadership position in the existing eye care businesses (ophthalmic prescription, surgical and contact lens care business), expand its skin care business to become a significant contributor to the company, pursue existing products into new specialties such as pediatrics and neurology, and invest in unique technologies.
 Ulmer has no immediate plans after he leaves Allergan. He joined the company in April 1967 as manager of Marketing Research. He held a variety of positions, including president, Allergan Pharmaceuticals and president, Allergan Medical Optics.
 Allergan, Inc., headquartered in Irvine, California, is a global provider of specialty therapeutic products; is expanding beyond skin care and its leadership position in eye care into adjacent markets; and is pursuing other core technologies.
 -0- 7/15/92
 /CONTACT: Shel Holtz (Media), 714-752-4387 (work), or 818-366-5296 (home), or Jeff D'Eliscu (Investor Relations) 714-752-4636 (work), 714-675-9475 (home) both of Allergan/
 (AGN) CO: Allergan, Inc. ST: California IN: MTC SU:


CH -- LA036 -- 9775 07/15/92 17:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 15, 1992
Words:468
Previous Article:HUFFY CORPORATION ANNOUNCES SECOND QUARTER RESULTS
Next Article:E-II HOLDINGS INC. FILES CHAPTER 11 REORGANIZATION PLAN
Topics:


Related Articles
ALLERGAN CONCLUDES SALE OF HUMPHREY DIVISION TO CARL ZEISS
ALLERGAN ANNOUNCES RETIREMENT OF DAVE BRUNS
(Repeating to fix garble at end of text)
IOMED AND ALLERGAN HERBERT ANNOUNCE COLLABORATIVE RESEARCH AGREEMENT AT MABON SECURITIES' DRUG DELIVERY CONFERENCE
CORRECTION TO ALLERGAN RESULTS.
HAUGEN NAMED ALLERGAN CHIEF OPERATING OFFICER AND ELECTED TO THE BOARD OF DIRECTORS
LIGAND AND ALLERGAN SIGN JOINT VENTURE AGREEMENT TO RESEARCH, DEVELOP AND COMMERCIALIZE RETINOID-BASED COMPOUNDS
ALLERGAN REPORTS SECOND QUARTER OPERATING RESULTS; EARNINGS PER SHARE FROM CONTINUING OPERATIONS INCREASE 31 PERCENT
WILSHIRE TECHNOLOGIES ANNOUNCES NEW PRESIDENT OF TRANSDERMAL PATCH DIVISION
AMYLIN PHARMACEUTICALS ELECTS NEW PRESIDENT AND CEO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters